Zoledronic acid for breast cancer that has spread to the bone
Part of Bones, joints & muscles, Cancer clinical trials.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have breast cancer that has been confirmed by a biopsy and has spread to the bone, which was first found on an MRI or CT scan.
- You must be planning to receive or have just started treatment with zoledronic acid.
- Your kidney function must be adequate (creatinine level ≤ 3.0 mg/dl and creatinine clearance ≥ 30 ml/min).
- Your blood calcium level must be in the normal range (2.0–3.0 mmol/L).
- You must be in good enough general health (ECOG score of 0, 1, or 2) to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
This trial tests a new medicine (JMT103) against a standard treatment (zoledronic acid) to see if it is better at preventing bone complications like fractures, pain, or needing radiation or surgery on the bones. It is for people whose cancer has spread to their bones.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
Hear when a new Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.